Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
in the TriNetX database. The GLP-1RAs include exenatide, liraglutide, dulaglutide, albiglutide, lixisenatide, and semaglutide. Obesity-related comorbid conditions include asthma, metabolic syndrome, gastroesophageal re fl ux disease, metabolic dysfunction – associated steatotic liver disease/steatohepatitis, obstructive sleep apnea, and osteoarthritis. New users were de fi ned as persons who received the fi rst GLP-1RA prescription during the study year/period. The age and sex standardization was conducted using the direct method, with the 2020 U.S. Census as the stand-ardpopulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Whitley, H. P., Trujillo, J. M., & Neumiller, J. J. (2023) · Clinical Diabetes · doi:10.2337/cd23-0023 · Cited by 132
Monitoring Report: GLP-1 RA Prescribing Trends - September 2024 DataPreprint
Gratzl, S., Rodriguez, P. J., Cartwright, B. M. G., Baker, C., & Stucky, N. L. (2024) · medRxiv · doi:10.1101/2024.01.18.24301500 · Cited by 29
Gregg, L. P., Worsley, M. L., Ramsey, D. J., Segar, M. W., Matheny, M. E., Virani, S. S., & Navaneethan, S. D. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000266 · Cited by 8
Cited by
Mahase, E. (2024) · BMJ · doi:10.1136/bmj.q1645 · Cited by 72
Macrophages and T cells in metabolic disorder-associated cancers
Taranto, D., Kloosterman, D. J., & Akkari, L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00743-1 · Cited by 85
“…drugs, particularly GLP-1R agonists, whose prescription rates have increased substantially for non-diabetic patients in the USA in recent years 247 , further investigations are warranted to dissect how these therapies alter the immune system and both local and systemic metabolic processes.”
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“In an analysis of one US health systems database a 700% increase in GLP-1 prescribing over the past four years was noted, primarily driven by prescriptions for obesity [138].”
Sheng‐Kai, K., Lo, J., Kyttaris, V. C., Tsokos, G. C., & Costenbader, K. H. (2024) · Arthritis & Rheumatology · doi:10.1002/art.43037 · Cited by 39
“8,9 In contrast, DPP4i, another class of oral hypoglycemic agents, work by preventing the degradation of glucagon-like peptide 1 (GLP1), which stimulates glucose-dependent insulin secretion and suppresses glucagon production, 10 resulting in a modest reduction in hemoglobin A1C (HbA1c).”
Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Nishida, K., Chrétien, B., Dolladille, C., Ebina, T., Aleksić, B., Cabé, N., Savey, V., Onoue, T., & Yatsuya, H. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.06.011 · Cited by 38
Auerbach, N., Liu, V. N., Huang, D. R., Clift, A. K., Al-Ammouri, M., & El-Osta, A. A. R. (2025) · BMJ Public Health · doi:10.1136/bmjph-2024-002519 · Cited by 31
“10 However, despite the substantial increase in uptake, barriers to adherence remain.”
Brosnihan, P., Luce, M. S., Yetasook, A. K., Perez, C., Scharf, K. R., & Aly, S. (2025) · The American Surgeon™ · doi:10.1177/00031348251337145 · Cited by 17
Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes
Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., Grams, M. E., Wright, D. R., Wang, V. H.-C., Rajan, A., Butt, E., Shin, J.-I., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2746 · Cited by 14
Eng, K., Zebardast, N., Boland, M. V., Lo, J., Swaminathan, S. S., Friedman, D. S., & Sheng‐Kai, K. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.10.029 · Cited by 13
Stone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 15
“As new drugs for type 2 diabetes continue to emerge, such as the increasing use of glucagon-like peptide-1 receptor agonists (GLP1RAs) 198 , it will be essential to follow their impact not only on cancer but also on ICI efficacy.”
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults
Hsu, A. H.-C., Ramirez, P. T., Chang, Y.-H., Chiang, Y. C., Santía, M. C., Meschini, T., Mateo-Kubach, P., Suri, A., & Kamat, A. A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.04.013 · Cited by 12
Jebeile, H., Danielsen, Y. S., Sumithran, P., Lorien, S. J., Jardine, I. R., Baur, L. A., & Lister, N. B. (2025) · Obesity Reviews · doi:10.1111/obr.70049 · Cited by 14
Murray, M. F., Dorsaint, T., Dougherty, E. N., Wildes, J. E., & Haedt‐Matt, A. A. (2024) · Body Image · doi:10.1016/j.bodyim.2024.101837 · Cited by 9
Shadbolt, C., Elkin, J., Schilling, C. G., Hua, X., Choong, P., & Dowsey, M. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02878 · Cited by 9
Asif, M., Asif, A., Rahman, U. A., Farooqi, H. A., Fatima, O., Ali, W., Jafar, U., & Amin, M. H. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70059 · Cited by 13
“Given these benefits, previous reports have demonstrated a significant increase in GLP-1RA usage over the past decade [16], suggesting the importance of investigating whether these medications may also play a role in ocular complications of diabetes.”
Ostrominski, J. W., Wagholikar, K. B., Olsson, K., Ünlü, O., Zelle, D., Kumar, S., Smith, A. M., Toliver, J. C., Michalak, W., Fabricatore, A. N., et al. (2024) · Obesity · doi:10.1002/oby.24186 · Cited by 8
Myers, W. K., Heath, G., & Rohrer, B. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.12.016 · Cited by 9
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
“20 This pleiotropic effectiveness profile has caused a major increase in use, 21 22 with recent estimates suggesting that one in eight adults (12”
Wu, J., Perez, A., & Sullivan, P. W. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.10.1029 · Cited by 7
Marshall, L. Z., Gleason, P. P., Friedlander, N., Farley, J., & Urick, B. Y. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.3.281 · Cited by 6
The evolving burden of obesity in the US: a novel population-level system dynamics approach
McEwan, P. C., Faurby, M. D., Lübker, C., Padgett, T., & Toliver, J. C. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2554518 · Cited by 9
“GLP-1 RA use for overweight and obesity in the US rose over 700% between 2019 and 2023 37 ; in 2023 and in 2025, approximately 12% of US adults reported taking a GLP-1 RA for either weight-loss or to treat a chronic condition such as diabetes or heart disease 38,39 .”
Ibrahim, S. S., Durrani, A. D., Ibrahim, M., Kuttner, N. P., Glivar, P., Singh, V. K., & Yu, E. M. (2026) · Global Spine Journal · doi:10.1177/21925682251415347 · Cited by 7
“All the studies were conducted in the U.S.”
Razavi, A. C., Troy, A. L., Patel, J., Mehta, L. S., Spitz, J. A., Lloyd‐Jones, D. M., Whelton, S. P., Johansen, M. C., & Blumenthal, R. S. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101724 · Cited by 8
Pladevall, M., ZIEMIECKI, R. M., Johannes, C. B., Khan, A. M., Mines, D. I., Ebert, N., Kovesdy, C. P., Thomsen, R. W., Baak, B. N., García‐Sempere, A., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01717-8 · Cited by 8
“…increased throughout the study period, with 1.6% to 4.8% of patients in each data source initiat‑ ing treatment in 2012 and 19.8% to 31.5% of patients in each data source initiating therapy in 2019, consistent with previous evidence showing increases in new users of GLP‑1 RA over time [21, 22].”
InfluentialFraming Obesity Beyond Disease: The Unintended Consequences of Not Casting a Wider Net
Wee, C. C. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0884 · Cited by 5
“The new highly effective weight loss agents have cosmetic and social bene fi ts and are in high demand (8) and ripe for misuse.”
Bank, N. C., Perle, S. J., Lauck, B. J., Rajesh, A. J., Jeffs, A. D., & Draeger, R. W. (2025) · Journal of Hand Surgery Global Online · doi:10.1016/j.jhsg.2025.100746 · Cited by 6
“20 The bene fi ts of GLP-1RA therapy in promoting glycemic regulation, weight loss, cardiovascular health, and chronic kidney disease prevention are well-substantiated.”
Liang, Y., Luo, S., Wan, E. Y. F., Cheung, C., Gill, D., & Yeung, S. L. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16171 · Cited by 7
Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward
Toro-Tobón, D., Ospina, N. S., & Brito, J. P. (2025) · Thyroid · doi:10.1089/thy.2024.0690 · Cited by 8
Global uptake of GLP-1 receptor agonists in obese, non-diabetic patients with cardiovascular disease
Chi, K., Pollanen, S., Hu, J., Lee, P., Mangalesh, S., Ezenna, C. G., Joseph, M., Krishna, M. M., Lin, Y.-S., Acero, L. M. R., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf104 · Cited by 3
Wallach, J. D., O’Malley, S. S., Lipska, K. J., Ross, J. S., Jeffery, M. M., & Savitz, S. T. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001575 · Cited by 3
GLP1 Receptor Agonist Induced Guttate Psoriasis in an Adult Female
Cook, S., & Selby, T. (2025) · SKIN The Journal of Cutaneous Medicine · doi:10.25251/skin.9.3.9 · Cited by 4
Chan, S., Yeo, Y. H., Kim, H., Delk, M., Polpichai, N., Danpanichkul, P., & Ting, P. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09494-x · Cited by 4
“The TriNetX platform has been validated for retrospective cohort studies and complies with HIPAA regulations [19, 20].”
Self-citationSeven unanswered questions about blockbuster weight-loss drugs
May, M. J. (2024) · Nature Medicine · doi:10.1038/s41591-024-03380-1 · Cited by 3
Gavin, K. L., Amjad, R., Makris, V., & Neuner, J. M. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.12.1311 · Cited by 2
Mai, Z., Kornak, J., Dufault, S. M., Strand, M. W., Reikes, A., & Watanabe, J. H. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251384637 · Cited by 2
“5,6 This points to potential differences in how this drug is prescribed or tolerated relative to semaglu-tide’s other formulations, such as Wegovy or Rybelsus.”
Cheng, D., Ji, H., Theodosakis, N., Noe, M. H., Chen, S. T., & Sheng‐Kai, K. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.02.008 · Cited by 5
Varghese, J. S., Hsiao, T. W., Fede, L., Chizak, C., Gocke, C., Waller, L. A., & Ali, M. (2026) · Obesity · doi:10.1002/oby.70141 · Cited by 2
“…cross-sectional analysis of of expensive but effective incretin mimetic drugs, such as semaglutide or tirzepatide, may result in faster declines of overweight and obesity in some counties more than others because of access disparities between sociodemographic groups or by insurance status [23].”
Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients
Kutler, R. B., Lin, A., Zhang, L., Trackey, P., Rivera‐Diaz, A., Jelić, S., St‐Onge, M., & Cai, Y. (2026) · Otolaryngology · doi:10.1002/ohn.70231 · Cited by 2
Chen, H. A., McIntyre, M. K., Kakadiya, J., Rai, P., Essibayi, M. A., Salim, H. A., Azzam, A. Y., Latifikhereshky, S., Yedavalli, V. S., Altschul, D., et al. (2026) · Stroke · doi:10.1161/strokeaha.126.055692 · Cited by 3
Gmehlin, C. G., Nemet, M., Rizwan, Z. M., Ahmad, S. R., Gajic, O., & Tekin, A. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001263 · Cited by 6
Age, race and ethnicity, and sex of participants in clinical trials related to obesity
Schumacher, L. M., Chibueze, J., Knudsen, F. M., Rajpal, A., Kalala, S., Power, K., Silver, J. K., & Murray, H. B. (2025) · Obesity · doi:10.1002/oby.24273 · Cited by 1
“Moving forward, it is important to include more older adults in a wide range of obesity-related trials, including drug trials [34], given this treatment ’ s rising popularity [35].”
Teratogenic risks of treated and untreated maternal obesity
Jones, R. E., & Zera, C. (2025) · Seminars in Perinatology · doi:10.1016/j.semperi.2025.152081 · Cited by 2
Wilson, L. M., & Anderson, T. S. (2025) · Neurology · doi:10.1212/wnl.0000000000213739 · Cited by 1
Sen, S., Pai, S., & Harbell, M. W. (2025) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001522 · Cited by 1
Gradually, then Suddenly: Nutrition in an Era of Medically Induced Weight Loss
Bergia, R. E., Davis, E. M., & Campbell, W. W. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.09.033 · Cited by 1
Obesity Management: Implications for Contraceptive Counseling and Reproductive Health
Palmer, V., Grunvald, E. L., Sannidhi, D., & Mody, S. K. (2025) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-025-00445-x · Cited by 2
“Moreover, the majority of patients seeking weight loss treatments are female [12, 13].”
Dameron, L., Bank, N. C., Raghava, N., Himmelberg, S. M., & Knoll, G. M. (2026) · Journal of Hand Surgery Global Online · doi:10.1016/j.jhsg.2025.100923 · Cited by 1
“12,13 Our study found that active GLP-1 RA prescriptions in the perioperative period were associated with significantly higher rates of scarring, postoperative pain, and wound complications at both 90 days and 1 year following TFR. Notably, although the difference in repeat TFR at 90 days was not…”
Hsu, J., Ho, B., Sayed, R., Patel, N. T. P., & Dardik, A. (2026) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2026.02.003 · Cited by 2
Chuang, S., Khetpal, V., Lu, F. Q., & Wu, W. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103304 · Cited by 1
Lee, C.-H. J., Qian, Y., Yu, W., Cusin, C., & Sheng‐Kai, K. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121487 · Cited by 1
Do, S., Christensen, K., Inneh, A., Peasah, S. K., & Good, C. B. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.5.625 · Cited by 4
Simadibrata, D. M., Al-Fakhouri, Z., Alomari, L., & Wong, R. C. K. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10001-z · Cited by 1
“In particular, the rapid expansion of incretin-based therapies in 2022 may suggest this increased trend of drug-induced AP based on our ITS analysis, as supported by large-scale analyses linking these medications to an increased risk of pancreatitis [10, 28].”
Peng, D. S., Shen, A., Smart, C. N., & Galamgam, J. (2026) · JAAD Case Reports · doi:10.1016/j.jdcr.2026.06.006 · Cited by 1
Glucagon‐like peptide‐1 receptor agonist use and violent crime among US adults
Semenza, D. C., & Thomas, C. (2026) · Criminology · doi:10.1111/1745-9125.70058 · Cited by 3
Hammond, M. M., Krishnan, V., Petito, L. C., Kazi, D. S., Khan, S. S., & Huang, X. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046302 · Cited by 1
Khani, E., Asham, H., Rezabakhsh, A., Babaei, S., & Entezari‐Maleki, T. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70248 · Cited by 2
Kawkgi, O. M. E. (2025) · Clinical Thyroidology · doi:10.1089/ct.2025;37.33-36 · Cited by 1
Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure
Hansell, C. E., Aneis, H., Kitsios, G. D., Bain, W., Zhao, Y., Suber, T. L., Evankovich, J. W., Sharma, L., Ramakrishnan, S. K., Prendergast, N. T., et al. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001247 · Cited by 4
Rezaie, A., & Yeo, Y. H. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.09.002
Self-citationMuayad, J., Chauhan, M. Z., Loya, A., Hussain, Z. S., Alsoudi, A. F., Francesco, T. D., & Ahmed, I. I. K. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.10.028
Auerbach, N., Liu, V. N., Huang, D. R., Clift, A. K., Al-Ammouri, M., & El-Osta, A. A. R. (2024) · Research Square · doi:10.21203/rs.3.rs-5689779/v1
Al-Shudifat, M., Sumra, B., Kocherry, C., Shamim, H., Jhakri, K., & Khan, S. (2025) · Cureus · doi:10.7759/cureus.78570 · Cited by 5
Chen, A. S., Brunetto, W. L., Canavan, M., Lipska, K. J., Richey, E. A., Wilson, M. S., Zarro, J., & Ross, J. S. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09691-4 · Cited by 1
Playter, K. P., Chen, Y.-H., Grant, A. R., Chen, Y., Travers, H. I., Hollenbeck, B. L., Nin, D. Z., Niu, R., Talmo, C. T., Chang, D., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7490872/v1
Association of Patient Cost-Sharing With Adherence to GLP-1a and Adverse Health Outcomes
Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., E. Grams, M., Wright, D. R., Hsing-Chun Wang, V., Rajan, A., Butt, E., Shin, J.-I., et al. (2025) · Figshare · doi:10.60929/nyulangone.28995647
Khela, H. S., Kishan, A., Manriquez, A. H., Kirby, L., Chisango, Z. M., Carayannopoulos, N. L., Singh, M., Cottrill, E. J., Avedian, R. S., Kleck, C. J., et al. (2026) · Spine Open · doi:10.1097/bn9.0000000000000051
The ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs
Nogrady, B. (2026) · Nature · doi:10.1038/d41586-026-00228-1
Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy
Madej, J., Gonzaga, E. R., & Naveed, M. (2026) · ACG Case Reports Journal · doi:10.14309/crj.0000000000002032
“3,4 Given that 86.5% of RYGB patients regain greater than 10% of maximal weight loss, GLP-1 RAs are considered a promising option to boost postprandial GLP-1 levels years after surgery, potentially counteracting metabolic adaptation and supporting long-term weight reduction.”
InfluentialLai, J. C. (2026) · IIC - International Review of Intellectual Property and Competition Law · doi:10.1007/s40319-026-01692-y
Journal club: GLP-1 receptor agonists in idiopathic intracranial hypertension
Cleaver, J., O’Connor, E., White, L. M., & Wakerley, B. R. (2026) · Practical Neurology · doi:10.1136/pn-2025-005071
Martino, J. A., Oles, A. R., Rogalski, B. L., Eichinger, J. K., & Friedman, R. J. (2026) · Shoulder & Elbow · doi:10.1177/17585732261434004
Rapid Resolution of Psoriatic Arthritis Symptoms Following Initiation of a GLP-1 Receptor Agonist
Gelman, B. K., & Capito, J. E. (2026) · West Virginia Medical Journal · doi:10.21885/wvmj.2026.05
Dacon, C., Kale-Pradhan, P. B., & Lipari, M. (2026) · Journal of Pharmacy Practice · doi:10.1177/08971900261449175 · Cited by 1
Exercise Snacks in Adults Living With Obesity: Protocol for a Randomized Feasibility Trial
McCarthy, S. F., Harness, E., Mulkewich, N., Sandilands, R. E., Marcotte‐Chénard, A., Islam, H., Richards, D. L., Madden, K. M., Singer, J., Jung, M. E., et al. (2026) · JMIR Research Protocols · doi:10.2196/100108
“While there has been a large surge in antiobesity medications (eg, glucagon-like peptide-1 receptor agonists) in recent years [55], nonpharmaceutical treatments for obesity are still critical, as these medications may not be accessible (due to high cost), manageable (due to potential side effects),…”
Malone, S. K., Glenn, A. J., Paulhamus, D. R., & Patterson, F. (2026) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2026.105902
Frankenfeld, C. L., Movva, N., Hooda, N., Gauthier, J., Reichert, H., & Doepker, C. L. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101685
Exercise and glucagon-like peptide 1 receptor agonists in cardiovascular disease beyond weight loss
Jordan, A. J., & McDermott, M. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01560-6
Feeding the invaders: how metabolic imbalance shapes infection and biofilm development
Mahajan, S., Macdowell, S., Mitchem, C. F., Alexander, E., & Wozniak, D. J. (2026) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuag029 · Cited by 2
“With the rise of infections and metabolic disorders, and the expanding clinical use of GLP-1 receptor agonists (Yeo et al. 2024 ), further investigation is required to determine how their use influences immune cell plasticity and whether they affect pathogenic bacterial behavior.”
Chen, J., Patel, R., Mikati, H., Mangray, S., Salluzzo, J. L., Bickston, S. J., & Tariq, R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100727
GLP-1 medications: use and interest in a representative survey of Finns
Jallinoja, P. T., Pietiläinen, K. H., & Chang, V. W. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02149-5 · Cited by 2
Reynolds, K. R., O’Malley, K. M., Roy, J. A., & Dave, C. V. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00860
GLP-1 prescribing for individuals with schizophrenia-spectrum disorders in a safety net hospital
Khan, S., Browne, J., Schwarz, A. G., Weinberg, J., Gouse, B. M., & Brown, H. E. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.08.002
Appetite-suppressing drugs and emerging implications for sustainability
O’Bryan, C. J., Szczepanik, M., Martens, P., Yong, J. W. H., & de Vos, P. (2026) · npj Sustainable Agriculture · doi:10.1038/s44264-026-00186-1
Lalani, I., Nambayan, R., Carbonell, C., Ruan, Y., O'Sullivan, D. E., Stukalin, I., Hilsden, R. J., & Brenner, D. R. (2026) · Cancer Control · doi:10.1177/10732748261483767 · Cited by 1
“4 Despite notable short-term weight loss outcomes, concerns persist about noted side effects 12-16 and the potential increased risk of certain cancers, such as thyroid cancer.”
Kazi, M. A. I., Khan, J., Mufarrih, S. M., Siddiqui, M., Ansari, H. U. H., Ahmed, M., Qureshi, I., Al-Sabban, A. M., Karnik, N. P., Gilman, A. J., et al. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01523-w
“In a nationwide analysis of U.S. electronic health records, more than 870,000 individuals initiated GLP-1 RA therapy between 2011 and 2023, with the steepest rise occurring after 2020; among individuals without diabetes, new GLP-1 RA use increased by more than 700% between 2019 and 2023 [ 48 ].”
Adipocytes as a Mechanistic Link Between Incretin-Based Therapies and Hair Loss
Gupta, A. K., Kaur, J., Piguet, V., & Mirmirani, P. (2026) · Biology · doi:10.3390/biology15181642
“Consequently, prescription of these incretin-based drugs has begun to expand to a broader range of patient populations [3,4].”
Genetically Proxied GIP ‐ GIPR Pathway Perturbation and Fracture Risk
Cheng, W., Liu, W., Wei, J., Zeng, C., Lyu, H., & Zhao, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71378
Boerhaave Syndrome: Case Report on a Rare Complication of Semaglutide Use
McMahon, M., Smithwick, L., Madsen, A., Whitt, E., & Warmbrod, B. (2026) · Cureus · doi:10.7759/cureus.117633
Metadata
- Authors
- Yeo, Y. H., Rezaie, A., Hsieh, T. Y.-J., Hu, X., Gaddam, S., Ma, K. S.-K., Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group, Mohamed, G., Lee, G. Y., Huang, P.-C., Watson, R., Mohamed, G., Lee, G. Y., Huang, P.-C., & Watson, R.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- Corresponding author
- Yeo, Yee Hui
- Rezaie, Ali
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2024-09
- Volume
- 177
- Issue
- 9
- Pages
- 1289-1291
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4400874445
- Cited by
- 90
- References
- 3
- Citations by year
- 2026: 41 · 2025: 38 · 2024: 11
- FWCI
- 29.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- GLP-1 receptor agonists, prescribing trends, medication use, type 2 diabetes, anti-obesity drugs, prescribing patterns
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Practice Patterns, Physicians', Drug Prescriptions, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.